RSV jab reduced infant hospital admissions by 83%, study reports
BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2988 (Published 28 December 2023) Cite this as: BMJ 2023;383:p2988
- Elisabeth Mahase
- The BMJ
The long acting monoclonal antibody nirsevimab (marketed as Beyfortus) reduced respiratory syncytial virus associated hospital admissions in infants by 83%, a study has found.1
More than 8000 infants aged 12 months or under in France, Germany, and the UK took part in the study and were randomly assigned to either receive nirsevimab (4037 infants) or standard care (no intervention, 4021 infants) before or during their first RSV season (September and October 2022).
The study, funded by the drug companies Sanofi and AstraZeneca, reported that 11 infants (0.3%) in the nirsevimab group and 60 (1.5%) in the standard group were …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.